Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
8
Not yet recruiting, industry sponsors, Rare and genetic disease, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed111
8 trials
Showing 1 to 8, recently updated first.
- An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)Not yet recruiting
ShionogiIndustry
NCT07750990 · 60 participants (planned) · Start Mar 31, 2027 · Primary completion Aug 31, 2028
Drug: S-606001; ERT · For: Pompe Disease
- Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)Not yet recruiting
Azafaros B.V.Industry
NCT07715084 · 20 participants (planned) · Start Jan 25, 2027 · Primary completion Jan 2028
Drug: AZ-3102 · For: Gaucher Disease Type 3
Sites: Jaipur, India; New Delhi, India; Lahore, Pakistan · 7 sites in all
- Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal DisordersPivotal-lookingNot yet recruiting
Azafaros B.V.Industry
NCT07885917 · 218 participants (planned) · Start Dec 10, 2026 · Primary completion Apr 1, 2030
Drug: AZ-3102 · For: Niemann-Pick Disease Type C; GM2 Gangliosidosis; GM1 Gangliosidosis and 1 more
- Pilot Study of TTI-0102 in CystinosisNot yet recruiting
Thiogenesis Therapeutics, Inc.Industry
NCT07837726 · 6 participants (planned) · Start Oct 2026 · Primary completion Dec 2026
Drug: TTI-0102 (cysteamine-pantetheine disulfide) · For: Nephropathic Cystinosis; Cystinosis
- Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIBNot yet recruiting
NeuroGTIndustry
NCT07818759 · 9 participants (planned) · Start Jan 18, 2027 · Primary completion Dec 31, 2028
Drug: rAAV9-CMV-hNAGLUop · For: Sanfilippo Syndrome (MPS III)
Sites: St Louis, Missouri
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)Not yet recruiting
Polaryx Therapeutics, Inc.Industry
NCT07740512 · 24 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2028
Drug: PLX-200 · For: Lysosomal Storage Disorders; Sandhoff Disease; Krabbe Disease and 2 more
- A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's DiseaseNot yet recruiting
Shanghai Vitalgen BioPharma Co., Ltd.Industry
NCT07603050 · 12 participants (planned) · Start May 14, 2026 · Primary completion May 29, 2028
Drug: VGN-R08b; VGN-R08b and 1 more · For: Gaucher Disease Type 3
Guangzhou Jiayin Biotech LtdIndustry
NCT06819514 · 16 participants (planned) · Start Mar 1, 2025 · Primary completion Mar 15, 2028
Drug: EXG110 Injection · For: Fabry Disease
Sites: Nanjing, China; Hangzhou, China · 3 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.